The Tumour, Nodes, Metastases (TNM) Classification system, published by the International Union Against Cancer, is the gold standard cancer staging system used worldwide ([@bib15]). Its objectives include assisting in the planning of therapy, informing prognosis, allowing evaluation of results and facilitating information exchange between treatment centres, and is updated periodically to incorporate evidence-based evolution ([@bib15]). However, the 2002 TNM sixth Edition (TNM6) has been considered to be a tool of limited prognostic value in oesophageal cancer (OC), mainly because lymph node (N) stage was limited by definition as a binary variable (N0 or N1), regardless of the actual lymph node metastasis count ([@bib16]).

The recently published TNM seventh edition (TNM7) replaced TNM6 with effect from 2010, and incorporated major modifications with regard to OC, in particular related to the individual T, N and M stage criteria, and stage groups ([@bib15]). Moreover, TNM7 introduced a new system of prognostic groups in which other prognostic variables are combined with T, N and M categories for stage I and II tumours, but not for stage III and IV tumours, where the prognostic grouping depends entirely on traditional T, N and M categories. TNM7 prognostic groupings also differ with regard to histopathological cell type. Prognostic grouping for both adenocarcinoma (ACA) and squamous cell carcinoma (SCC) takes account of tumour grade for stage I and II tumours, but for SCC, the anatomical site within the thoracic oesophagus is also incorporated for stage I and II tumours ([@bib15]). However, the principal TNM7 upgrade relates to the classification of lymph node stage, which has a major influence on defining specific stage groups. The number of lymph node metastases has long been considered to be the key and defining prognostic factor for patients diagnosed with OC ([@bib6]), and in addressing this issue TNM7 reclassifies lymph node positive tumours into four groups (N0-3) based on the relative burden of nodal metastases ([@bib15]). These groups are defined as N0, N1 (1--2 lymph nodes), N2 (3--6 lymph nodes) and N3 (\>6 lymph nodes). Stage groups have also been revised and expanded to account for this modified N stage.

The aims of this study therefore, were to determine the influence of the new TNM7 staging system on OC histopathological stage categorisation and related survival, when compared with historical control data derived with TNM6, and to determine the relative accuracy of TNM6 and TNM7 in predicting prognosis. The setting was a regional upper gastrointestinal cancer network in South Wales serving a population of 1.3 million.

Materials and methods
=====================

Consecutive patients who underwent potentially curative surgery for OC by a regional upper GI cancer network were identified from a prospectively maintained database. Patients were excluded if they had a complete pathological response to neoadjuvant treatment, involved longitudinal resection margins, high-grade dysplasia in the absence of invasive malignancy or if complete histological information on the numbers of involved lymph nodes was missing. Complete pathological data were available on 202 patients, all of whom underwent oesophagectomy between 1998 and 2010. The median age of the patients was 61 (range 35 to 79) years. There were 161 (79.7%) males and 41 (20.3%) females. A total of 169 patients had ACAs (83.7%) and 33 patients had SCCs (16.3%).

Preoperative staging involved computed tomography and endoluminal ultrasonography, and was in accordance with TNM6 definitions. All patients were discussed at a regional specialist multi-disciplinary team meeting with management plans individually tailored according to factors relating to both cormobidity and tumour stage. In general, fit patients with tumours of stage T3 and equivocal T4, N0 and N1 were considered for neoadjuvant therapy before surgery. Less fit patients and those with T1-2, N0 disease were considered for surgery alone. A total of 121 patients underwent standard subtotal oesophagectomy as described by [@bib7] and [@bib17]. Transhiatal resection, as described by [@bib10] was performed in 81 patients. This was employed selectively in patients with ACC of the lower third of the oesophagus who had significant cardiorespiratory co-morbidity. Neoadjuvant chemotherapy or chemoradiotherapy were given to 87 patients and 31 patients, respectively.

All patients were originally staged histopathologically in accordance with TNM6, and then retrospectively re-staged using TNM7. The primary outcome measure was survival. Clinical follow-up was 3 monthly intervals for the first year following surgery, decreasing to 6 monthly intervals thereafter for 5 years or until death. A total of 187 patients (92.6%) were followed-up for 5 years or until death. Death certification was obtained from the Office for National Statistics.

The regional ethics committee were contacted regarding this study, but a formal application was deemed unnecessary.

Statistical analysis
--------------------

Data were expressed as median (range). Methods appropriate for non-parametric data were used. Cumulative survival was calculated according to the life-table method of [@bib5], and differences in survival between groups of patients were analysed with the log-rank test. Multivariable analysis of factors influencing survival was performed using Cox\'s proportional hazards model ([@bib1]). The gradient of Schoenfeld (partial) residuals ([@bib14]) *vs* time was calculated using linear regression, for each of the variables entered into the multivariable model, in order to test for violations of the proportional hazards assumption. Data analysis was performed using SPSS version 18.0 (Chicago, IL, USA).

Results
=======

The T and N stages, stage groups and prognostic groups of the patients are shown in [Table 1](#tbl1){ref-type="table"}, and the proportion of patients who migrated between stages when TNM7 was applied are summarised in [Table 2](#tbl2){ref-type="table"}. There were no changes observed in OC pT stage, but significant changes were observed in pN stage. Of the 110 patients (54.5%) with lymph node metastases classified as pN1 by TNM6, 56 (27.7%) remained pN1, 35 (17.3%) were re-classified as pN2 and 19 (9.4%) patients were re-classified as pN3 by TNM7. With regard to stage groups, the number of patients with stage I disease almost doubled under TNM7, whereas in contrast the number of patients with stage II tumours was reduced by almost a third. The number of patients with stage III tumours increased slightly when classified by TNM7, whereas the number of patients with stage IV tumours remained unchanged. Downstage migration occurred in 20 (9.9%) patients when classified by TNM7 (stage II to I). Upstage migration occurred in 4 (2.0%) patients (stage II to III). When TNM7 prognostic group allocations were compared with TNM6 allocations, fewer were classified as stage I, and more were classified as stage II. The numbers of patients with stages III and IV tumours remained unchanged. Eleven patients from the early period of this series could not be allocated a prognostic group because of pathology reports that failed to comment on tumour grade.

Survival
--------

[Table 3](#tbl3){ref-type="table"} illustrates cumulative 5-year survival related to the stage. Survival related to TNM7 is shown separately. [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} demonstrate Kaplan--Meier survival curves for OC by TNM6 and TNM7 stage groups, and TNM7 prognostic groups.

For stage I OC, 5-year survival by TNM7 was poorer by 16.1% when compared with TNM6. In contrast stage II OC 5-year survival by TNM7 improved by 4.4%, and median survival improved by 17 months. Survival for patients with stage III and IV tumours remained the same. Allocation of TNM7 prognostic groups produced survival plots that were midway between those obtained with TNM6 and TNM7 stage groups for patients with stage I and II tumours, and were unchanged for patients with stage III and IV tumours.

Univariable analysis of the factors associated with survival is shown in [Table 4](#tbl4){ref-type="table"}. On multivariable analysis including the following variables: -- tumour grade, pT stage, TNM6 pN stage, TNM7 pN stage, TNM6 stage group, TNM7 stage group, TNM7 prognostic group and the number of lymph node metastases -- only the TNM7 prognostic group emerged as significantly and independently associated with survival ([Table 5](#tbl5){ref-type="table"}).

Further univariable and multivariable sub analyses, related to histopathogical cell type, of the factors associated with survival in the cohort of 169 ACA patients revealed an identical picture. The cohort of 33 SCC patients was considered too small to perform any meaningful survival analysis.

No significant violations of the proportional hazards assumption were identified by means of the gradient of Schoenfeld (partial) residuals *vs* time.

Discussion
==========

This represents the only Western study to date to compare the effects of the new TNM7 staging system to TNM6 for OC. The principal findings were that stage migration occurred in 11.9% of patients, and this resulted in significant artifactual change in survival rates for early stage disease (I and II), but no change in outcome for more advanced stage disease (III and IV). Prognosis was better predicted by TNM7 when compared with TNM6, and specifically by the new prognostic groups incorporated in TNM7. This datum therefore provides strong support for the updated TNM7 staging system for OC, and lends further weight to the validity of the data-driven approach used to derive this radical update ([@bib13]).

The study has several strengths. The patient numbers are relatively large by Western standards, and represent a consecutive series treated by a single UK cancer network. All patients received stage-directed treatment by a specialist regional multidisciplinary team with considerable experience in the treatment of oesophagogastric cancer. The surgery was performed by specialist upper GI surgeons whose results have been well audited ([@bib9]) and shown to be equivalent or better than those reported in the UK-based MRC OEO2 randomised trial ([@bib8]; [@bib9]). The patients resided in a well-defined geographical area, and the follow-up data is especially robust with dates and causes of death obtained from the Office of National Statistics.

Nevertheless, there are potential limitations. Although the numbers of patients were large for a single UK region, they are relatively small when compared with the large multicentre study undertaken to derive TNM7 for OC ([@bib13]). However Rice *et al* describe a patient series who underwent surgery alone, whereas our patients were treated in line with current UK practice, where neoadjuvant chemotherapy is the standard of care for locoregionally advanced OC ([@bib8]). In addition, total lymph node harvests were variable, with a median of 11 nodes (range 1--38) retrieved. We have reported previously that the prognosis of surgically resected OC is highly dependent on the numbers of lymph nodes examined pathologically, again arguably due to stage migration effects ([@bib18]). Hsu *et al* from Taiwan have recently reported a comparison of TNM6 *vs* TNM7 in surgically resected oesophageal SCC. Their findings confirmed the predictive value of the new pN and pM stage criteria and they concluded that TNM7 constituted an improvement over TNM6 in terms of informing outcome ([@bib4]). However, although their sample size was large (392), as might be expected from its geographical origin, this study consisted exclusively of patients diagnosed with squamous cell cancer, and it is therefore uncertain how applicable their conclusions are to patients diagnosed with ACA, the predominant Western tumour, which accounts for the vast majority (83.7%) of patients in this study. The cohort of patients diagnosed with SCC in this study was too small for valid comparison with the findings of Hsu *et al.*

Improving the accuracy of any given staging system represents a fundamental aim of modifying and upgrading prognostic models, and TNM7 appears to have been successful in this regard related to OC. Such a benefit must, however, be balanced against potential and inherent disadvantages of modifying histopathological staging. The 'Will Rogers Phenomenon\' is a perceived paradox named after a quote attributed to the US comedian and social commentator Will Rogers (1879--1935). Referring to migration during the American economic depression of the 1930s, he allegedly said"'When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states\'"

An analogous phenomenon is the concept of cancer stage migration, whereby changes in staging result in apparent differences in group outcomes, yet individual patient outcomes remain unchanged. The first report of this phenomenon described a cohort of lung cancer patients that had artifactually better stage-specific survival than historical controls from the same institution ([@bib2]). The difference was explained by the combination of both a prognostically favourable lead-time bias and stage migration, as a result of more advanced imaging techniques ([@bib2]). Changes in the rules governing the grading of prostate cancer biopsies, and improved histopathological processing of bladder cancer specimens, have produced similar stage migration effects in urological oncology ([@bib3]). In this study, significant yet purely artifactual changes in the survival of early-stage OC have been demonstrated, through the application of the TNM7 system, for the same reasons. Such changes may not only be mistakenly attributed to the effects of treatment, but also equally importantly risk preventing meaningful comparison of patient outcomes with historical controls, including those published in clinical trials. Indeed, our study indicates that it is now imperative for the results of clinical trials to be reported in relation to the TNM stage classification used. There is also a responsibility upon the clinicians involved in revising and updating the TNM staging system to ensure that modifications are based on the best available evidence, using pathological criteria that are known to be reproducible, to justify any concomitant problems that an update may bring. In the case of the colorectal-cancer TNM staging system, major concerns have been raised within the pathology community regarding modifications incorporated within TNM6 and TNM7 because of a perceived lack of a sound evidence base ([@bib12]; [@bib11]) and because of this, UK colorectal-cancer staging continues to be classified by means of TNM5, more than a decade after its publication ([@bib12])

In conclusion, TNM7 is a better prognostic tool than TNM6 for OC, predominantly due to the inclusion of the relative burden of the lymph node metastases count. Moreover, the new system of prognostic grouping in TNM7, taking account of tumour grade and site, has further refined staging accuracy when compared with the traditional anatomically based stage grouping. TNM7 should therefore also form the basis for the radiological reporting and staging of all modalities for OC. Notwithstanding the significant benefit TNM7 provides, clinicians must be aware of the Will Rogers Phenomenon in the context of cancer staging, and avoid drawing misleading conclusions when comparing current patient outcomes with those of historical controls.
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###### Details of the patients\' staging by TNM6 and TNM7

                           **TNM6**     **TNM7**
  ------------------------ ------------ ------------
  *T stage*                             
   T1                      29 (14.4)    29 (14.4)
   T2                      29 (14.4)    29 (14.4)
   T3                      130 (64.4)   130 (64.4)
   T4                      14 (6.9)     14 (6.9)
                                         
  *N stage*                             
   N0                      92 (45.5)    92 (45.5)
   N1                      110 (54.5)   56 (27.7)
   N2                      N/A          35 (17.3)
   N3                      N/A          19 (9.4)
                                         
  *Stage groupings*                     
   I                       23 (11.4)    43 (21.3)
   II                      80 (39.6)    56 (27.7)
   III                     93 (46.0)    97 (48.0)
   IV                      6 (3.0)      6 (3.0)
                                         
  *Prognostic groupings*                
   I                       N/A          27 (13.4)
   II                      N/A          61 (30.2)
   III                     N/A          97 (48.0)
   IV                      N/A          6 (3.0)
   Not determined          N/A          11 (5.4)

Abbreviations: N/A=not applicable; TNM=tumour, nodes, metastases.

Figures are number of patients (%).

###### Stage migration related to TNM7 classification
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###### Stage-by-stage patient survival

  **Survival**       **TNM6 stage groups**   **TNM7 stage groups**   **TNM7 prognostic groups**
  ------------------ ----------------------- ----------------------- ----------------------------
  *Stage I*                                                          
   Median (months)   N/A                     111                     111
   5 year (%)        78.3                    62.2                    67.7
                                                                      
  *Stage II*                                                         
   Median (months)   47                      64                      48
   5 year (%)        46.3                    50.7                    48.6
                                                                      
  *Stage III*                                                        
   Median (months)   23                      23                      23
   5 year (%)        18.3                    17.6                    17.6
                                                                      
  *Stage IV*                                                         
   Median (months)   13                      13                      13
   5 year (%)        0                       0                       0

Abbreviations: N/A=not applicable; TNM=tumour, nodes, metastases.

###### Univariable analysis of factors influencing survival

  **Variable**                      ***χ*^2^**   **DF**   ***P*-value**
  --------------------------------- ------------ -------- ---------------
  Age                               48.020       41       0.210
  Gender                            1.039        1        0.308
  Histological cell type            2.250        2        0.308
  Histological tumour grade         10.260       2        0.006
  Operative approach (TT *vs* TH)   0.795        1        0.373
  Neoadjuvant therapy               0.627        1        0.429
  T stage (same in TNM6 and TNM7)   21.514       3        \<0.0001
  N stage (TNM6)                    21.499       1        \<0.0001
  N stage (TNM7)                    37.509       3        \<0.0001
  Number of lymph node metastases   61.677       12       \<0.0001
  Stage groupings (TNM6)            36.587       4        \<0.0001
  Stage groupings (TNM7)            50.531       7        \<0.0001
  Prognostic groupings (TNM7)       47.147       7        \<0.0001

Abbreviations: DF=degrees of freedom; TH=trans hiatal; TNM=tumour, nodes, metastases; TT=trans thoracic.

###### Multivariable analysis of factors influencing oesophageal cancer survival

  **TNM7 prognostic stage**   **Hazard ratio**   **95% CI**   ***P*-value**   
  --------------------------- ------------------ ------------ --------------- ---------
  Stage IA                    Reference group                                 
  Stage IB                    3.901              1.034        14.721          0.045
  Stage IIA                   5.994              1.586        22.659          0.008
  Stage IIB                   4.346              1.303        14.503          0.017
  Stage IIIA                  5.734              1.743        18.869          0.004
  Stage IIIB                  10.838             3.244        36.211          \<0.001
  Stage IIIC                  13.130             3.873        44.511          \<0.001
  Stage IV                    11.565             2.743        48.760          \<0.001

Abbreviations: CI=confidence interval; TNM=tumour, nodes, metastases.
